<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640847</url>
  </required_header>
  <id_info>
    <org_study_id>106-10-201</org_study_id>
    <nct_id>NCT01640847</nct_id>
  </id_info>
  <brief_title>MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases</brief_title>
  <official_title>Phase II Trial of Phillips MRI-Guided High Intensity Focused Ultrasound (Sonalleve) and Lyso-thermosensitive Liposomal Doxorubicin (ThermoDox) for Palliation of Painful Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celsion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celsion</source>
  <brief_summary>
    <textblock>
      This study will evaluate treatment with High Intensity Focused Ultrasound (HIFU)in
      combination with ThermoDox (liposomal doxorubicin) is safe and effective in reducing pain for
      patients with painful bone metastases.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete pain response</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Painful Bone Metastases</condition>
  <condition>Breast Carcinoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm RT: HIFU plus ThermoDox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Index lesion has been treated with EBRT and is currently painful, but these subjects have already received their maximum cumulative EBRT dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm NRT: HIFU plus ThermoDox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects have no yet received any radiation to the index lesion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox</intervention_name>
    <arm_group_label>Arm RT: HIFU plus ThermoDox</arm_group_label>
    <arm_group_label>Arm NRT: HIFU plus ThermoDox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of breast carcinoma, non-small cell lung cancer, small cell
             lung cancer, or adenocarcinoma of the prostate

          -  Bone metastases index lesion in the ribs, clavicle, scapula, upper extremities,
             pelvis, or posterior aspects of the lumbar vertebra L3-L5 or sacral S1-S5.

          -  Patients will have failed at least one prior attempt or will not be eligible for
             external beam radiation therapy (EBRT)

        Exclusion Criteria:

          -  Greater than 450 mg/m2 of prior free doxorubicin and/or non-heat activated liposomal
             doxorubicin

          -  LVEF &lt; 50%

          -  Significant Cardiac History

          -  Brain Metastases

          -  Contraindication for MR imaging (as incompatible implanted metallic device, weight
             &gt;250 lbs etc) or known intolerance or allergy to MRI contrast agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Borys, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Celsion</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Painful bone metastases</keyword>
  <keyword>Bone Cancer</keyword>
  <keyword>Bone Cancer Pain</keyword>
  <keyword>Patients with</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Pain</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

